Abstract 470P
Background
Glioblastoma multiforme (GBM) is the most common malignant brain tumor. MRPs are involved in mitochondrial translation, with previously revealed role in cancer. Here we aimed to understand their role in GBM.
Methods
Differentially expressed genes (DEGs) were identified through the ‘DESeq2' on R and GEO2R. Survival analysis with optimal expression cutoff for Overall Survival (OS) and median cutoffs for Disease-Free Survival (DFS) based on TCGA-GBM was done using the ‘survival' and 'survminer' R packages, and GEPIA2 online tool. Gene Set Enrichment Analysis (GSEA) was performed using Enrichr tool. miRNA-mRNA networks were constructed using MultiMiR and CytoScape. Immune and methylation analyses were conducted using TIMER2.0 (XCELL) and cBioPortal.
Results
OS estimates indicated worse survival in patients with higher expression of selected MRPs (Table). Further analysis indicated that elevated expression of MRPS33 and MRPL23 is correlated with decreased DFS, with Hazard Ratios (HRs) of 1.80 (p = 0.0012) and 1.70 (p = 0.0039), respectively. GSEA on upregulated genes in high MRPS33-expressers revealed relations to PDGF, NCAM1 interactions, EMT, and integrins in angiognesis. miRNA-mRNA network has identified hub miRNAs, like hsa-miR-1-3p, to have validated interactions with MRPs of interest. Expression of MRPL41, MRPL35, and MRPS33, had negative correlations with HM27/HM450 methylation (Spearman's rho = -0.41, -0.20, and -0.19, respectively; p < 0.05). Finally, there was a positive correlation between MRPS33 expression and Macrophage M2 infiltration in GBM (rho = 0.393, p < 0.05). Table: 470P
Selected MRPs gene expression and GBM patient survival, HR > 1 suggests a harmful effect of the gene on survival
Gene | HR | P Value | 95% CI | DE |
MRPL41 | 1.732784 | 0.0047 | (1.35, 2.11) | D |
MRPL32 | 1.946699 | 0.0010 | (1.55, 2.34) | U |
MRPL17 | 1.787801 | 0.0070 | (1.37, 2.21) | U |
MRPL23 | 1.689083 | 0.0103 | (1.29, 2.09) | U |
MRPS33 | 1.58498 | 0.0226 | (1.19, 1.98) | U |
DE: Differential expression (GBM relative to normal) across GSE4290, GSE68848, and TCGA-GBM (overlap); U: Upregulated; D: Downregulated.
Conclusions
Our study identified a complex multi-omic framework through which MRPs are regulated and play their prognostic and tumorigenic roles in GBM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
469P - Detection of circulating tumor DNA (ctDNA) in cerebrospinal fluid (CSF) in patients with glioblastoma treated in phase I clinical trial
Presenter: Marie Porte
Session: Poster session 16
471P - PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma
Presenter: Eugenia Cella
Session: Poster session 16
472P - Comprehensive quinomics assessment of BPM31510IV treatment in advanced glioblastoma multiforme patients
Presenter: Seema Nagpal
Session: Poster session 16
473P - A novel machine learning (ML) model integrating clinical and molecular data to predict response to second-line treatment in recurrent IDHwt-glioblastoma (rGBM)
Presenter: Maurizio Polano
Session: Poster session 16
474P - Potassium inward rectifier channel subfamily J member 11 mRNA expression in glioma and its significance in predicting prognosis and chemotherapy sensitivity
Presenter: kaijia zhou
Session: Poster session 16
Resources:
Abstract
475P - Optimising genomic testing for patients with central nervous system (CNS) tumours using oxford nanopore technology
Presenter: Alona Sosinsky
Session: Poster session 16
476P - The role of androgen receptor expression and epigenetic regulation in adult-type diffuse gliomas
Presenter: VINCENZO DI NUNNO
Session: Poster session 16
477P - ENHO's protective role in lower grade glioma
Presenter: Osama Younis
Session: Poster session 16
478P - Molecular characterization of adult non-glioblastoma central nervous system (CNS) tumors to identify potential targettable alterations
Presenter: Marta Padovan
Session: Poster session 16